Objective Calcification of the aortic valve and adjacent structures involves inflammatory, lipid and mineral metabolism pathways. We hypothesised that circulating biomarkers reflecting these pathways are associated with cardiac calcification in older adults.
Methods We investigated the associations of various biomarkers with valvular and annular calcification in the Cardiovascular Health Study. Of the 5888 participants, up to 3585 were eligible after exclusions for missing biomarker, covariate or echocardiographic data. We evaluated analytes reflecting lipid (lipoprotein (Lp) (a), Lp-associated phospholipase A2 (LpPLA2) mass and activity), inflammatory (interleukin-6, soluble (s) CD14) and mineral metabolism (fetuin-A, fibroblast growth factor (FGF)-23) pathways that were measured within 5 years of echocardiography. The relationships of plasma biomarkers with aortic valve calcification (AVC), aortic annular calcification (AAC) and mitral annular calcification (MAC) were assessed with relative risk (RR) regression.
Results Calcification was prevalent: AVC 59%, AAC 45% and MAC 41%. After adjustment, Lp(a), LpPLA2 mass and activity and sCD14 were positively associated with AVC. RRs for AVC per SD (95% CI) were as follows: Lp(a), 1.051 (1.022 to 1.081); LpPLA2 mass, 1.036 (1.006 to 1.066) and LpPLA2 activity, 1.037 (1.004 to 1.071); sCD14, 1.039 (1.005 to 1.073). FGF-23 was positively associated with MAC, 1.040 (1.004 to 1.078) and fetuin-A was negatively associated, 0.949 (0.911 to 0.989). No biomarkers were significantly associated with AAC.
Conclusion This study shows novel associations of circulating FGF-23 and fetuin-A with MAC, and LpPLA2 and sCD14 with AVC, confirming that previously reported for Lp(a). Further investigation of Lp and inflammatory pathways may provide added insight into the aetiology of AVC, while study of phosphate regulation may illuminate the pathogenesis of MAC.
Statistics from Altmetric.com
This work was presented, in part, at the American College of Cardiology Scientific Sessions, San Diego, California, 2015
Contributors Conception or design of the work: AEB and JRK. Data collection: MiC, JHI, MaC, AR, EB and JSG. Data analysis and interpretation: TMB, AEB, MiC, JHI, MaC, AR, DO, EB, JSG, DSS and JRK. Drafting the article: AEB and JRK. Critical revision of the article: AEB, TMB, MiC, JHI, MaC, AR, DO, EB, DSS, JSG and JRK. Final approval of the version to be published: AEB, TMB, MiC, JHI, MaC, AR, DO, EB, JSG, DSS and JRK.
Funding This work was supported by R01 HL-094555, as well as by contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086 and grant U01HL080295 from the National Heart, Lung and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by R01AG023629 from the National Institute on Aging. AEB is supported by a fellowship from the Empire Clinical Research Investigator Program. A full list of principal Cardiovascular Health Study investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Competing interests MC and JRK have received research funding from diaDexus (manufacturer of the LpPLA2 test). JRK reports ownership of stock in Pfizer and Gilead Sciences.
Ethics approval Institutional Review Board approval received at each participating institution.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement De-identified data from the Cardiovascular Health Study can be obtained from the USA National Institutes of Health (BioLINCC) by members of the research community.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.